US FDA explores how best to detect risk of drug-induced liver injury
This article was originally published in SRA
Executive Summary
The Food and Drug Administration is to hold a meeting to discuss its July 2009 guidance on drug-induced liver injuries (DILIs) and explore how best to detect and assess the severity, extent and likelihood of DILIs in people using drugs for any medical purpose1.